Evidence map›Paper›PMID 31797084›Full record

SynthesisJournal of neurology2020

Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Lu Xu, Tanxin Liu, Lili Liu, Xiaoying Yao, Lu Chen, Dongsheng Fan, Siyan Zhan, Shengfeng Wang

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 177 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06782958 phase1enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of FHND1002 Granules After Single and Multiple Doses in Healthy Adult Volunteers

TypeinterventionalSponsorJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Ran2024 to 2025Enrolled72ConditionsAmyotrophic Lateral Sclerosis (ALS)Arms50mg FHND1002, 100mg FHND1002, 150 mg FHND1002, 200 mg FHND1002（fasting）, 250mg FHND1002
NCT07138014 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of FHND1002 Granules in Patients With Amyotrophic Lateral Sclerosis (ALS)

TypeinterventionalSponsorJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Ran2025 to 2028Enrolled180ConditionsAmyotrophic Lateral Sclerosis (ALS)ArmsFHND1002 100mg, FHND1002 200mg, Placebo
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Article
  19. Article
  20. Beneficial Effects of Putative Hydrogen Sulfide (HMolecules (Basel, Switzerland) · 2026
    Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lu XuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Tanxin LiuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Lili LiuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Xiaoying YaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
Lu ChenDepartment of Neurology, Peking University Third Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-7359-7683
Dongsheng FanDepartment of Neurology, Peking University Third Hospital, Beijing, China.
Siyan ZhanDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China. siyan-zhan@bjmu.edu.cn.ORCID http://orcid.org/0000-0001-7252-5349
Shengfeng WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China. Shengfeng1984@126.com.

Funding

National Natural Science Foundation of China 91646107
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a global disease, which adversely affects the life quality of patients and significantly increases the burden of families and society. We aimed to assess the changing incidence, prevalence of ALS around the world.

methodsWe searched Medline, Embase, Web of Science, and Cochrane library to identify articles published until September 9, 2018. Each included study was independently reviewed for methodological quality by two reviewers. We used a random-effects model to summarize individual studies and assessed heterogeneity (I

resultsWe identified 124 studies that were eligible for final inclusion, including 110 studies of incidence and 58 studies of prevalence. The overall crude worldwide ALS prevalence and incidence were 4.42 (95% CI 3.92-4.96) per 1,00,000 population and 1.59 (95% CI 1.39-1.81) per 1,00,000 person-years, respectively. ALS prevalence and incidence increased by age until the age of 70-79. Since 1957, incidence has been significantly rising year by year, and this upward trend was weakened after standardization. The longest survival time were in Asia (ranging from 3.74 years in South Asia to 9.23 years in West Asia).

conclusionsWith the aggravation of population aging and the rapid growth of economy, developing regions following the development pattern of the developed regions may suffer rising ALS prevalence and incidence which may increase their disease burden as well. These data highlight the need for research into underlying mechanism and innovations in health-care systems.

Indexed as

Amyotrophic Lateral SclerosisGlobal HealthHumansIncidencePrevalenceAmyotrophic lateral sclerosisIncidenceMeta-analysisPrevalence

Identifiers

PMID31797084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.